To drop or not to drop the antiplatelet agent, that is the question for patients with atrial fibrillation and chronic coronary syndrome undergoing percutaneous coronary intervention

Cardiol J. 2020;27(1):1-3. doi: 10.5603/CJ.2020.0012.

Authors

Yongcheol Kim¹, Thomas W Johnson², Young-Hoon Jeong³

Affiliations

¹ Division of Cardiology, Chonnam National University Hospital, Gwangju, Republic of Korea. goodoctor@naver.com.
² Department of Cardiology, Bristol Heart Institute, Bristol, United Kingdom.
³ Department of Internal Medicine, Gyeongsang National University School of Medicine and Cardiovascular Center, Gyeongsang National University Changwon Hospital, Changwon, Republic of Korea.

No abstract available

Publication types

Editorial
Comment

MeSH terms

Atrial Fibrillation*
Humans
Percutaneous Coronary Intervention*
Platelet Aggregation Inhibitors
ST Elevation Myocardial Infarction*

Substances

Platelet Aggregation Inhibitors